Skip to Main Content

More than one in four biotechs that went public in 2020 are trading below cash, according to a new STAT analysis of data from the financial database provider Sentieo.

The indicator — which means a company has more cash on hand than its overall public valuation — seems like further, glaring evidence that too many biotechs raced to market in 2020, a favorite hypothesis among investors whose life science portfolios have plummeted this year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment